The CryoLife O'Brien stentless porcine aortic bioprosthesis: 5-year follow-up

Ann Thorac Surg. 2001 Jan;71(1):86-91. doi: 10.1016/s0003-4975(00)01823-3.

Abstract

Background: Mortality, morbidity, complication rates, and echo hemodynamic results using the Cryolife O'Brien stentless aortic bioprosthesis over a 5-year period are reported.

Methods: The stentless valve was implanted in 97 conscecutive patients, 54 male and 43 female, mean age 70.9 +/- 6.5 years. All patients underwent preoperative, discharge (early study), 6-month (intermediate study), and late (18.3 +/- 10.4 months) echocardiography.

Results: The actuarial 5-year survival rate was 93.9% +/- 3%. Aortic regurgitation was absent in 95.5%, mild in 3.4%, and moderate in 1.1%. Peak and mean systolic gradients were significantly lower at discharge (p < 0.001) and at the 6-month follow-up (p < 0.001) but did not significantly fall further at the late study (p = NS). The effective orifice area index at discharge (p < 0.001) and at 6 months (p < 0.001) differed significantly from preoperative values, but variations at late study were not significant (p = NS). Left ventricular mass index decreased early postoperatively (p < 0.001) and at 6-month assessment (p < 0.001) with a further significant reduction at late echocardiography (p = 0.04).

Conclusions: The 5-year results of this stentless valve showed a low rate of valve-related complications with excellent hemodynamic performance in all valve sizes.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Aortic Valve Insufficiency / mortality
  • Aortic Valve Insufficiency / surgery
  • Aortic Valve Stenosis / mortality
  • Aortic Valve Stenosis / surgery
  • Bioprosthesis*
  • Female
  • Follow-Up Studies
  • Heart Valve Prosthesis*
  • Humans
  • Male
  • Middle Aged
  • Prosthesis Design
  • Survival Rate